Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T; Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hatanaka T, et al. Among authors: hirooka m. J Gastroenterol Hepatol. 2025 Jan 6. doi: 10.1111/jgh.16871. Online ahead of print. J Gastroenterol Hepatol. 2025. PMID: 39762722
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Tanaka H, Nishikawa H, Shibata H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T. Ohama H, et al. Among authors: hirooka m. Sci Rep. 2025 Jan 2;15(1):72. doi: 10.1038/s41598-024-78539-4. Sci Rep. 2025. PMID: 39747852 Free PMC article.
Clinical factors to predict changes of esophagogastric varices after sustained viral response with direct-acting antiviral therapy.
Watanabe T, Tokumoto Y, Ochi H, Mashiba T, Tada F, Hiraoka A, Kisaka Y, Tanaka Y, Yagi S, Nakanishi S, Sunago K, Yamauchi K, Higashino M, Hirooka K, Tange M, Yukimoto A, Morita M, Okazaki Y, Hirooka M, Abe M, Hiasa Y. Watanabe T, et al. Among authors: hirooka m. J Gastroenterol. 2024 Nov 15. doi: 10.1007/s00535-024-02174-z. Online ahead of print. J Gastroenterol. 2024. PMID: 39545995
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice.
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F, Nakamura S, Nakamura Y, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; RELPEC Group and HCC 48 Group. Hiraoka A, et al. Among authors: hirooka m. Hepatol Res. 2024 Nov 11. doi: 10.1111/hepr.14136. Online ahead of print. Hepatol Res. 2024. PMID: 39526824
Prognostic impact of age on outcomes of hepatic decompensation in patients with compensated cirrhosis (CHESS2102): an international, multicenter cohort study.
Liu S, Li J, Wong Y, Yim HJ, Hirooka M, Enomoto H, Xie Q, Dai E, Hanafy AS, Cao Z, Zhao L, Teh KB, Kim TH, Jung YK, Koizumi Y, Hiasa Y, Nishimura T, Iijima H, Tian Q, Guo X, Jia Y, Sun J, Liu C, Qi X. Liu S, et al. Among authors: hirooka m. MedComm (2020). 2024 Nov 3;5(11):e781. doi: 10.1002/mco2.781. eCollection 2024 Nov. MedComm (2020). 2024. PMID: 39492833 Free PMC article.
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.
Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Mascia L, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Rimini M. Persano M, et al. Among authors: hirooka m. Oncology. 2024 Oct 11:1-13. doi: 10.1159/000541018. Online ahead of print. Oncology. 2024. PMID: 39396495
Guidelines for the diagnosis and treatment of idiopathic portal hypertension, extrahepatic portal obstruction, and Budd-Chiari syndrome in Japan.
Furuichi Y, Kage M, Ohta M, Ohfuji S, Sasaki H, Hidaka H, Yoshida H, Kanto T, Kusano H, Akahoshi T, Obara K, Hashizume M, Kuniyoshi Y, Kawaguchi T, Okubo H, Ishikawa T, Hirooka M, Iwakiri Y, Nio M, Tanaka A. Furuichi Y, et al. Among authors: hirooka m. Hepatol Res. 2024 Nov;54(11):952-969. doi: 10.1111/hepr.14118. Epub 2024 Oct 4. Hepatol Res. 2024. PMID: 39364631
336 results